115 related articles for article (PubMed ID: 16520920)
1. To: Scholtz HE, Pretorius SG, Wessels DH, Becker RHA (2005) Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 48:1988-1995.
DeVries JH
Diabetologia; 2006 May; 49(5):1125-6. PubMed ID: 16520920
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
Scholtz HE; Pretorius SG; Wessels DH; Becker RH
Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
4. Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers.
Rave K; Nosek L; Heinemann L; Frick A; Becker R
Diabetes Metab; 2003 Sep; 29(4 Pt 1):430-1. PubMed ID: 14526272
[No Abstract] [Full Text] [Related]
5. Equipotency of insulin glargine and regular human insulin on glucose disposal in healthy subjects following intravenous infusion.
Scholtz HE; Pretorius SG; Wessels DH; Venter C; Potgieter MA; Becker RH
Acta Diabetol; 2003 Dec; 40(4):156-62. PubMed ID: 14740274
[TBL] [Abstract][Full Text] [Related]
6. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.
Kuerzel GU; Shukla U; Scholtz HE; Pretorius SG; Wessels DH; Venter C; Potgieter MA; Lang AM; Koose T; Bernhardt E
Curr Med Res Opin; 2003; 19(1):34-40. PubMed ID: 12661778
[TBL] [Abstract][Full Text] [Related]
7. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
Peterson GE
Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of insulin detemir and insulin glargine assessed by an isoglycemic clamp method in healthy cats.
Gilor C; Ridge TK; Attermeier KJ; Graves TK
J Vet Intern Med; 2010; 24(4):870-4. PubMed ID: 20561185
[TBL] [Abstract][Full Text] [Related]
9. Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine.
Gerich J; Becker RH; Zhu R; Bolli GB
Diabetes Technol Ther; 2006 Apr; 8(2):237-43. PubMed ID: 16734552
[TBL] [Abstract][Full Text] [Related]
10. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
11. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
[TBL] [Abstract][Full Text] [Related]
12. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery.
Yeldandi RR; Lurie A; Baldwin D
Diabetes Technol Ther; 2006 Dec; 8(6):609-16. PubMed ID: 17109592
[TBL] [Abstract][Full Text] [Related]
13. Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers.
Li J; Wang Y; Han L; Sun X; Yu H; Yu Y
Clin Ther; 2012 Dec; 34(12):2333-8. PubMed ID: 23195963
[TBL] [Abstract][Full Text] [Related]
14. Relating glucose clamp profiles to reduction of blood glucose after insulin administration.
Woodworth JR; Howey DC; Bowsher RR; Brunelle RL
Diabetes Technol Ther; 2004 Apr; 6(2):147-53. PubMed ID: 15117581
[TBL] [Abstract][Full Text] [Related]
15. Insulin detemir (levemir), a new long-acting insulin.
Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
[TBL] [Abstract][Full Text] [Related]
16. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
[TBL] [Abstract][Full Text] [Related]
17. Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats.
Marshall RD; Rand JS; Morton JM
J Vet Pharmacol Ther; 2008 Jun; 31(3):205-12. PubMed ID: 18471141
[TBL] [Abstract][Full Text] [Related]
18. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
Becker RH; Nowotny I; Teichert L; Bergmann K; Kapitza C
Diabetes Obes Metab; 2015 Mar; 17(3):261-7. PubMed ID: 25425394
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.
Ocheltree SM; Hompesch M; Wondmagegnehu ET; Morrow L; Win K; Jacober SJ
Eur J Endocrinol; 2010 Aug; 163(2):217-23. PubMed ID: 20508081
[TBL] [Abstract][Full Text] [Related]
20. [Insulin glargine improves fasting blood glucose levels in prepubertal children with unsatisfactorily controlled type 1 diabetes].
Mianowska B; Szadkowska A; Czerniawska E; Pietrzak I; Bodalski J
Pediatr Endocrinol Diabetes Metab; 2007; 13(4):189-93. PubMed ID: 18042313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
